Back to results
US 2010/0305188 A1Published application
Nucleic acid capable of regulating the proliferation of cell
AssigneeKyowa Hakko Kirin Co., Ltd.
InventorsHaruo Nakano, Tatsuya Miyazawa, Yoji Yamada, Tetsuo Yoshida
Life of this patent
Estimating the term…
Abstract
Provided are an agent for suppressing or promoting cell proliferation, a diagnostic reagent or therapeutic drug for a disease resulting from a cell proliferation abnormality, an agent for inducing apoptosis, an agent for suppressing or promoting the expression of a target gene for a nucleic acid such as a microRNA, and a method of suppressing or promoting cell proliferation.
Claims12
-32. (canceled)
A method of suppressing or promoting cell proliferation in a patient, which method comprises administering to the patient a nucleic acid selected from the group consisting of:
- (a1) a nucleic acid consisting of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (b1) a nucleic acid consisting of 17 to 28 sequential nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (c1) a nucleic acid having 90% or more identity to one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (d1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261 and 2315-2321;
- (e1) a nucleic acid comprising the 2nd to 8th nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (f1) a nucleic acid consisting of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- (g1) a nucleic acid having 90% or more identity to any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- and
- (h1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314 and 2322-2328, thereby suppressing or promoting cell proliferation in the patient.
14 more elements
A method of suppressing or promoting cell proliferation in a patient, which method comprises administering to a patient:
- (a2) a nucleic acid complementary to a nucleic acid selected from the group consisting of (a1) a nucleic acid consisting of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (b1) a nucleic acid consisting of 17 to 28 sequential nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (c1) a nucleic acid having 90% or more identity to one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (d1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261 and 2315-2321;
- (e1) a nucleic acid comprising the 2nd to 8th nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (f1) a nucleic acid consisting of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- (g1) a nucleic acid having 90% or more identity to any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- and (h1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314 and 2322-2328;
- (b2) a vector that expresses a nucleic acid selected from the group consisting of (a1) a nucleic acid consisting of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (b1) a nucleic acid consisting of 17 to 28 sequential nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (c1) a nucleic acid having 90% or more identity to one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (d1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261 and 2315-2321;
- (e1) a nucleic acid comprising the 2nd to 8th nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (f1) a nucleic acid consisting of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- (g1) a nucleic acid having 90% or more identity to any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- and (h1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314 and 2322-2328;
- (c2) a vector that expresses a nucleic acid complementary to a nucleic acid selected from the group consisting of (a1) a nucleic acid consisting of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (b1) a nucleic acid consisting of 17 to 28 sequential nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (c1) a nucleic acid having 90% or more identity to one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (d1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261 and 2315-2321;
- (e1) a nucleic acid comprising the 2nd to 8th nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (f1) a nucleic acid consisting of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- (g1) a nucleic acid having 90% or more identity to any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- and (h1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314 and 2322-2328;
- (d2) a substance that suppresses or promotes the expression of a gene having a target nucleotide sequence for a nucleic acid selected from the group consisting of (a1) a nucleic acid consisting of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (b1) a nucleic acid consisting of 17 to 28 sequential nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (c1) a nucleic acid having 90% or more identity to one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (d1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261 and 2315-2321;
- (e1) a nucleic acid comprising the 2nd to 8th nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (f1) a nucleic acid consisting of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- (g1) a nucleic acid having 90% or more identity to any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- and (h1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314 and 2322-2328;
- (e2) a nucleic acid that suppresses or promotes the expression of a gene having a target nucleotide sequence for a nucleic acid selected from the group consisting of (a1) a nucleic acid consisting of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (b1) a nucleic acid consisting of 17 to 28 sequential nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (c1) a nucleic acid having 90% or more identity to one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (d1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261 and 2315-2321;
- (e1) a nucleic acid comprising the 2nd to 8th nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (f1) a nucleic acid consisting of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- (g1) a nucleic acid having 90% or more identity to any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- and (h1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314 and 2322-2328;
- (f2) a siRNA that that suppresses or promotes the expression of a gene having a target nucleotide sequence for a nucleic acid selected from the group consisting of (a1) a nucleic acid consisting of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (b1) a nucleic acid consisting of 17 to 28 sequential nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (c1) a nucleic acid having 90% or more identity to one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (d1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261 and 2315-2321;
- (e1) a nucleic acid comprising the 2nd to 8th nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (f1) a nucleic acid consisting of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- (g1) a nucleic acid having 90% or more identity to any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- and (h1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314 and 2322-2328;
- or
- (g2) a vector that expresses the nucleic acid of (e2),
- thereby suppressing or promoting cell proliferation in the patient.
96 more elements
A method of treating a disease resulting from a cell proliferation abnormality in a patient, which method comprises administering to a patient with a disease resulting from a cell proliferation abnormality an effective amount of:
- (a3) a nucleic acid selected from the group consisting of (a1) a nucleic acid consisting of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (b1) a nucleic acid consisting of 17 to 28 sequential nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (e1) a nucleic acid having 90% or more identity to one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (d1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261 and 2315-2321;
- (e1) a nucleic acid comprising the 2nd to 8th nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (f1) a nucleic acid consisting of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- (g1) a nucleic acid having 90% or more identity to any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- and (h1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314 and 2322-2328;
- (b3) a nucleic acid complementary to the nucleic acid of (a3);
- (c3) a vector that expresses the nucleic acid of (a3);
- (d3) a vector that expresses the nucleic acid of (b3);
- (e3) a substance that suppresses or promotes the expression of a gene having a target nucleotide sequence for the nucleic acid of (a3);
- (f3) a nucleic acid that suppresses or promotes the expression of a gene having a target nucleotide sequence for the nucleic acid of (a3);
- or
- (g3) a vector that expresses the nucleic acid of (f3), thereby treating the disease in the patient.
20 more elements
A method of treating a disease resulting from a cell proliferation abnormality in a patient, which method comprises administering to a patient with a disease resulting from a cell proliferation abnormality an effective amount of:
- (a4) a nucleic acid selected from the group consisting of (a1) a nucleic acid consisting of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (b1) a nucleic acid consisting of 17 to 28 sequential nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (c1) a nucleic acid having 90% or more identity to one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (d1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261 and 2315-2321;
- (e1) a nucleic acid comprising the 2nd to 8th nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (f1) a nucleic acid consisting of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- (g1) a nucleic acid having 90% or more identity to any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- and (h1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314 and 2322-2328;
- (b4) a nucleic acid complementary to the nucleic acid of (a4);
- or
- (c4) a nucleic acid that suppresses or promotes the expression of a gene having a target nucleotide sequence for the nucleic acid of (a4), thereby treating the disease in the patient.
16 more elements
A method of diagnosing a disease resulting from a cell proliferation abnormality in a patient, which method comprises:
- (ia) obtaining a sample from a patient,
- (iia) measuring the expression level of a nucleic acid selected from the group consisting of (a1) a nucleic acid consisting of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (b1) a nucleic acid consisting of 17 to 28 sequential nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (c1) a nucleic acid having 90% or more identity to one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (d1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261 and 2315-2321;
- (e1) a nucleic acid comprising the 2nd to 8th nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (f1) a nucleic acid consisting of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- (g1) a nucleic acid having 90% or more identity to any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- and (h1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314 and 2322-2328, and
- (iiia) comparing the expression level obtained in (iia) with the expression level in normal tissue, or
- (ib) obtaining a sample from a patient, and
- (iib) detecting a mutation of the nucleic acid or the genome that encodes the nucleic acid,
- thereby diagnosing a disease resulting from a cell proliferation abnormality in the patient.
18 more elements
A method of suppressing or promoting expression of a target gene in a patient comprising administering to a patient:
- (a5) a nucleic acid selected from the group consisting of (a1) a nucleic acid consisting of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (b1) a nucleic acid consisting of 17 to 28 sequential nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (c1) a nucleic acid having 90% or more identity to one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (d1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261 and 2315-2321;
- (e1) a nucleic acid comprising the 2nd to 8th nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (f1) a nucleic acid consisting of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- (g1) a nucleic acid having 90% or more identity to any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- and (h1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314 and 2322-2328;
- (b5) a nucleic acid complementary the nucleic acid of (a5);
- (c5) a vector that expresses the nucleic acid of (a5);
- or
- (d5) a vector that expresses the nucleic acid of (b5),
- thereby suppressing or promoting expression of a target gene in the patient.
18 more elements
A method of screening for an agent that promotes or suppresses cell proliferation, which method comprises:
- (i) measuring a first expression level of a nucleic acid selected from the group consisting of (a1) a nucleic acid consisting of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (b1) a nucleic acid consisting of 17 to 28 sequential nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (c1) a nucleic acid having 90% or more identity to one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (d1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261 and 2315-2321;
- (e1) a nucleic acid comprising the 2nd to 8th nucleotides of any one of SEQ ID NO:
- 1-939, 2057-2132, 2212-2261, and 2315-2321;
- (f1) a nucleic acid consisting of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- (g1) a nucleic acid having 90% or more identity to any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314, and 2322-2328;
- and (h1) a nucleic acid that hybridizes under stringent conditions with a complementary strand of any one of SEQ ID NO:
- 940-2056, 2133-2211, 2262-2314 and 2322-2328 in a cell that expresses the nucleic acid;
- (ii) bringing a test substance into contact with the cell of (i),
- (iii) measuring a second expression level of the same nucleic acid;
- and
- (iv) comparing the first and second expression levels, wherein a change in the first and second expression levels indicates that the test substance is an agent that promotes or suppresses cell proliferation.
17 more elements
Dependencies are inferred from the claim text.